ALX Oncology (NasdaqGS:ALXO) FY Conference Transcript

Summary of ALX Oncology FY Conference Call Company Overview - Company: ALX Oncology (NasdaqGS:ALXO) - Key Programs: Evorpacept and ALX 2004, both in clinical stages and differentiated in their class [2][3] Core Industry Insights - Focus on CD47: Evorpacept targets CD47, a critical immune checkpoint in oncology, which has been challenging to target effectively [3][4] - EGFR-targeted ADC: ALX 2004 is a novel antibody-drug conjugate (ADC) targeting EGFR, designed to minimize on-target toxicity while maximizing efficacy [21][22] Key Data and Findings - Evorpacept Data: - Presented at SITC with promising results in gastric cancer (Aspen-06) showing a 65% response rate in CD47 overexpressing HER2-positive patients, a significant improvement over the control arm [12][14] - Combination studies with Rituxan and Evorpacept showed complete response rates of 83% and 92% in different settings [13] - ALX 2004 Progress: - Currently in phase one trials, with successful completion of initial dose cohorts and a focus on optimizing the linker payload for better delivery and efficacy [4][31] - Preclinical data indicates superior bystander effects and reduced toxicity compared to existing EGFR-targeted therapies [27][29] Market Opportunity - HER2-positive Breast Cancer: - Estimated addressable patient population of 20,000, with a market opportunity valued between $2 billion to $4 billion [20] - Current treatments show response rates of 15% to 20%, indicating a significant unmet need for effective therapies post-HER2 treatment [19] Strategic Collaborations - Partnerships: Collaborations with Sanofi for combination studies in multiple myeloma, leveraging the high expression of CD47 in hematologic malignancies [46][47] Future Catalysts - Upcoming Data Releases: - Interim data for Evorpacept expected in Q3 2026, which will be crucial for validating the biomarker-driven approach [33] - Continued dose escalation and data sharing for ALX 2004 to elucidate its safety profile [34] Conclusion - ALX Oncology is positioned to potentially lead in the CD47 and EGFR-targeted therapy spaces with differentiated mechanisms and promising clinical data, addressing significant unmet medical needs in oncology [35][36]